(Q43670537)

25 November 2017

title

Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study (English)

1 reference

25 November 2017

1 reference

D J Hoban

1

1 reference

25 November 2017

S K Bouchillon

2

1 reference

25 November 2017

J L Johnson

3

1 reference

25 November 2017

G G Zhanel

4

1 reference

25 November 2017

D L Butler

5

1 reference

25 November 2017

L A Miller

6

1 reference

25 November 2017

J A Poupard

7

1 reference

25 November 2017

Gemifloxacin Surveillance Study Research Group

8

1 reference

25 November 2017

language of work or name

1 reference

1 May 2001

1 reference

Diagnostic Microbiology and Infectious Disease

25 November 2017

published in

1 reference

25 November 2017

volume

40

1 reference

25 November 2017

issue

1-2

1 reference

25 November 2017

page(s)

51-57

1 reference

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Antipneumococcal activities of gemifloxacin compared to those of nine other agents

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

Comparative in vitro activity of gemifloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900241-3

7 January 2021

10.1016/S0732-8893(01)00241-3

Identifiers

DOI

1 reference

25 November 2017

1 reference